Anzeige
Mehr »
Dienstag, 16.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14X6S | ISIN: US15870P3073 | Ticker-Symbol: 2I3
Tradegate
16.09.25 | 16:25
6,000 Euro
-14,89 % -1,050
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CHAMPIONS ONCOLOGY INC Chart 1 Jahr
5-Tage-Chart
CHAMPIONS ONCOLOGY INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,8006,00022:59
5,8006,00022:00

Aktuelle News zur CHAMPIONS ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
00:30Champions Oncology targets sequential revenue growth and margin expansion as radiopharma and data platforms advance1
CHAMPIONS ONCOLOGY Aktie jetzt für 0€ handeln
MoEarnings Call Transkript: Champions Oncology übertrifft im 1. Quartal 2026 die Gewinnerwartungen2
MoChampions Oncology, Inc.: Champions Oncology Reports Quarterly Revenue of $14.0 Million256Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational...
► Artikel lesen
MoCHAMPIONS ONCOLOGY, INC. - 10-Q, Quarterly Report6
MoCHAMPIONS ONCOLOGY, INC. - 8-K, Current Report3
MoChampions Oncology Non-GAAP EPS of $0.02 beats by $0.03, revenue of $14M beats by $0.49M2
FrInsights Ahead: Champions Oncology's Quarterly Earnings1
MiChampions Oncology, Inc.: Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025279HACKENSACK, NJ / ACCESS Newswire / September 10, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions...
► Artikel lesen
23.07.CHAMPIONS ONCOLOGY, INC. - 10-K, Annual Report1
23.07.Champions Oncology, Inc.: Champions Oncology Reports Record Annual Revenue of $57 Million284Total annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced...
► Artikel lesen
21.07.CHAMPIONS ONCOLOGY, INC. - 8-K, Current Report1
21.07.Champions Oncology, Inc.: Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025245HACKENSACK, NJ / ACCESS Newswire / July 21, 2025 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report...
► Artikel lesen
18.07.Champions Oncology Names New CEO1
18.07.Champions Oncology names Rob Brainin as new CEO5
18.07.Champions Oncology, Inc.: Champions Oncology Announces Appointment of New CEO474HACKENSACK, NJ / ACCESS Newswire / July 18, 2025 / Champions Oncology (NASDAQ:CSBR), a leading provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing, today...
► Artikel lesen
08.07.Champions Oncology lanciert Plattform für radiopharmazeutische Dienstleistungen, erweitert seine Isotopen-Lizenz und screent über 30 PDX-Modelle318Erweitertes Angebot ermöglicht integrierte radiopharmazeutische Studien unter Einsatz von klinisch relevanten Isotopen und hochgradig charakterisierten PDX-Tumormodellen HACKENSACK...
► Artikel lesen
08.07.Champions Oncology startet Plattform für radiopharmazeutische Dienstleistungen2
08.07.Champions Oncology, Inc.: Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models837Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champions...
► Artikel lesen
28.04.Champions Oncology, Inc.: Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House301HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical...
► Artikel lesen
28.04.Champions Oncology secures license for radionuclide studies1
Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1